1106 completed, 80 unknown, 77 recruiting, 67 terminated. 1466 Phase 3, 136 Phase 2.
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler - Asthma | Phase 3 | Not yet recruiting | Chiesi Farmaceutici S.p.A. | 700 | 2026-11-16 | 2026-10-05 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Almirall, S.A. | 230 | 2026-11-01 | 2026-10-14 |
| Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Galderma R&D | 240 | 2026-10-08 | 2026-10-16 |
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | Pfizer | 1100 | 2026-09-30 | 2026-10-09 |
| Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 246 | 2026-09-22 | 2026-10-09 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Novartis Pharmaceuticals | 382 | 2026-09-21 | 2026-10-13 |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis Dupilumab Injection, IBI3027 - Atopic Dermatitis | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 520 | 2026-09-15 | 2026-10-15 |
| A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) HFA-152a, HFA-134a - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 110 | 2026-09-01 | 2026-09-30 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2) GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 370 | 2026-08-27 | 2026-09-30 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 514 | 2026-08-27 | 2026-09-25 |
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy | Phase 3 | Recruiting | Novartis Pharmaceuticals | 576 | 2026-08-27 | 2026-10-13 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Tilrekimig, Dupilumab, Placebo for Tilrekimig - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 1375 | 2026-08-24 | 2026-10-22 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | Pfizer | 1100 | 2026-08-20 | 2026-10-30 |
| Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets, Rupatifen Fumarate Capsules Placebo - Seasonal Allergic Rhinitis | Phase 3 | Recruiting | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | 550 | 2026-08-18 | 2026-09-09 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema Tilrekimig, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 375 | 2026-08-17 | 2026-10-15 |
| Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis Stapokibart, Placebo - Seasonal Allergic Rhinitis (SAR) | Phase 3 | Recruiting | Chengdu Kangnuoxing Biopharma,Inc. | 136 | 2026-08-13 | 2026-09-03 |
Showing 20 of 1466. Sign in to see all of them.
Asthma (605) · Dermatitis, Atopic (233) · Rhinitis, Allergic, Seasonal (127) · Rhinitis, Allergic (117) · Rhinitis, Allergic, Perennial (82) · Eczema (75) · Conjunctivitis, Allergic (65) · Angioedemas, Hereditary (60) · Chronic Urticaria (47) · Eosinophilic Esophagitis (28) · Dermatitis (27) · Rhinitis (26) · Lung Diseases (24) · Sarcoidosis (21)
Immune System Diseases (1449) · Hypersensitivity, Immediate (1364) · Respiratory Tract Diseases (895) · Respiratory Hypersensitivity (889) · Lung Diseases (604) · Bronchial Diseases (603) · Lung Diseases, Obstructive (590) · Skin and Connective Tissue Diseases (396) · Skin Diseases (375) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (304) · Otorhinolaryngologic Diseases (297) · Genetic Diseases, Inborn (294) · Nose Diseases (292) · Rhinitis (263)
Budesonide (83) · Fluticasone (77) · Albuterol (53) · montelukast (53) · Budesonide, Formoterol Fumarate Drug Combination (49) · Mometasone Furoate (44) · Formoterol Fumarate (42) · dupilumab (42) · Beclomethasone (40) · Omalizumab (39) · ciclesonide (38) · Salmeterol Xinafoate (28) · Fluticasone-Salmeterol Drug Combination (25) · benralizumab (25) · desloratadine (23)
AstraZeneca (135) · GlaxoSmithKline (86) · Organon and Co (84) · Novartis Pharmaceuticals (53) · Sanofi (32) · Teva Branded Pharmaceutical Products R&D, Inc. (30) · ALK-Abelló A/S (28) · Shire (25) · Eli Lilly and Company (23) · Chiesi Farmaceutici S.p.A. (22) · Boehringer Ingelheim (21) · Pfizer (21) · Regeneron Pharmaceuticals (20) · Sumitomo Pharma America, Inc. (20) · Milton S. Hershey Medical Center (17)
United States (642) · Germany (304) · Canada (272) · Poland (233) · Spain (226) · France (198) · United Kingdom (192) · Japan (183) · Italy (179) · Hungary (151) · China (150) · Australia (137) · Argentina (135) · South Korea (122) · Netherlands (121)
Catherine Bonuccelli (11)
PMID 36472162, PMID 36326435, PMID 39588375, PMID 27881132, PMID 31319851, PMID 33826132, PMID 35636689, PMID 42162528, PMID 34389504, PMID 40993471, PMID 32926419, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 39393433, PMID 40028832, PMID 20818886, PMID 23312695, PMID 29174062, PMID 30954640, PMID 31066001, PMID 32180164, PMID 33165005, PMID 33453450, PMID 34037993, PMID 34142350, PMID 36749121, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 22329608, PMID 23548529, PMID 23878046, PMID 24712435, PMID 24966061, PMID 25685162, PMID 26054553, PMID 26369589, PMID 26498386, PMID 26612545, PMID 26704701, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29536781, PMID 29655772, PMID 29656145
2023 (28), 2018 (23), 2017 (21), 2015 (19), 2016 (18), 2019 (14), 2009 (11), 2014 (11), 2025 (9), U10HL098115 (7), 2004 (6), 2008 (6), U10HL074073 (5), U10HL074204 (5), U10HL074208 (5)